Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
XL092 + Atezolizumab vs Regorafenib in Metastatic Colorectal Cancer
NCT05425940Phase 3Active, not recruiting
- Sponsor
- Exelixis, Inc.
- Start
- Sep 2022
- Primary completion
- Jun 2026
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 16
01
Overview
A Phase 3 trial of zanzalintinib in colorectal cancer (CRC), sponsored by Exelixis, Inc.. Started Sep 2022; status: active, not recruiting.
02
Drugs
zanzalintinib
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT05425940.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05425940.